Cam Gallagher bought stock once, on Dec 29, 2025
Director at Opus Genetics, Inc., and 1 other company
SEC CIK 0001557832 · Filings on SEC.gov ↗
Cam Gallagher's record
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Companies
Every filing
39 filings since Nov 2020, newest first
Opus Genetics, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Pres, Interim CFO
Zentalis Pharmaceuticals, Inc.
President
Zentalis Pharmaceuticals, Inc.
President
Zentalis Pharmaceuticals, Inc.
President
Zentalis Pharmaceuticals, Inc.
President
Zentalis Pharmaceuticals, Inc.
President
Zentalis Pharmaceuticals, Inc.
President
Zentalis Pharmaceuticals, Inc.
President
Zentalis Pharmaceuticals, Inc.
President
Zentalis Pharmaceuticals, Inc.
President
Zentalis Pharmaceuticals, Inc.
President
Zentalis Pharmaceuticals, Inc.
President
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
Zentalis Pharmaceuticals, Inc.
Director
About Cam Gallagher
Cam Gallagher, MBA, is a seasoned biotechnology executive with over 30 years of experience in the life sciences industry, specializing in new company formation, corporate development, marketing, operations, and early-stage investing.( He currently serves as President and CEO of Alessa Therapeutics, a clinical-stage drug development company focused on localized drug delivery for prostate cancer, and as a board member for Opus Genetics, Inc. (NASDAQ: IRD), where he has been a director since January 2019 and Chair since December 2019; he also sits on the boards of SelectION, Immusoft, and UC San Diego Moores Cancer Center.(
Gallagher's career highlights include co-founding and serving as President and board member of Zentalis Pharmaceuticals (NASDAQ: ZNTL) from 2014 to 2024, Chief Business Officer at RetroSense Therapeutics (acquired by Allergan in 2016), and founding board member at VelosBio (acquired by Merck for $2.8B in 2020).( He co-founded Nerveda, LLC, a life science seed fund, and held management roles at Oncternal, Zavante, Verus Pharma, CV Therapeutics, and Dura Pharma. Gallagher recently purchased 83,000 shares of Opus Genetics stock on December 29, 2025, at $1.97 per share, signaling confidence in the company.( He holds an MBA from the University of San Diego and a BS (or BBA) in Business Administration from Ohio University.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.